Skip to main content

4 Result(s)

within Ryo Ariyasu Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)

    For patients with locally advanced non-small-cell lung cancer (LA-NSCLC) that progressed after definitive chemoradiotherapy (CRT) and durvalumab consolidation therapy, no subsequent standard treatment exists. ...

    Tsukasa Hasegawa, Ryo Ariyasu, Hisashi Tanaka… in Cancer Chemotherapy and Pharmacology (2023)

  2. No Access

    Article

    Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients

    Soluble interleukin-2 receptor (sIL-2R) suppresses effector T-cells. Few studies have assessed serum sIL-2R in patients receiving immunotherapy. We evaluated the association between serum sIL-2R levels and the...

    Takehiro Tozuka, Noriko Yanagitani, Hiroshi Yoshida… in Investigational New Drugs (2023)

  3. No Access

    Article

    EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy

    Data on the re-administration of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) after osimertinib failure in patients with T790M-positive non–small cell lung cancer (NSCLC) is limite...

    Shinsuke Ogusu, Ryo Ariyasu, Takahiro Akita, Ayu Kiritani… in Investigational New Drugs (2022)

  4. No Access

    Article

    Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms

    Patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer with BIM deletion polymorphism may have a limited response to EGFR tyrosine kinase inhibitors (EGFR-TKIs). However, some re...

    Ryo Ariyasu, Noriko Yanagitani, Kenichi Tadokoro… in Cancer Chemotherapy and Pharmacology (2020)